What are the functions and effects of enzalutamide? How does it help treat prostate cancer?

Enzalutamide is an antiandrogen drug widely used in the treatment of prostate cancer, especially in the treatment of castration-resistant prostate cancer (CRPC). It inhibits the action of androgen receptors, thereby preventing androgens (such as testosterone) from stimulating cancer cells and slowing down the growth and spread of cancer cells. Through this mechanism, enzalutamide significantly improves survival in patients with advanced prostate cancer, especially in those who have already undergone other treatments (such as castration therapy), showing significant clinical benefit.

The main mechanism of action of enzalutamide is to prevent the effects of androgens on prostate cancer cells by binding to androgen receptors. Androgens are the main hormones in the male body. After binding to androgen receptors, they promote the growth and spread of cancer cells. Enzalutamide competitively binds to androgen receptors, inhibits the activity of androgen receptors, and reduces the dependence of cancer cells on androgens, thereby preventing the proliferation and spread of cancer cells. In addition, enzalutamide can also prevent androgen receptors from entering the cell nucleus, further inhibiting the transcriptional activity of cancer cells, achieving anti-cancer effects.

Enzalutamide has achieved significant efficacy in the treatment of castration-resistant prostate cancer (CRPC). According to clinical studies, enzalutamide can significantly prolong progression-free survival (PFS) and overall survival (OS) in patients with advanced prostate cancer. Enzalutamide provides an important treatment option for patients whose tumors progress despite conventional hormonal therapy. Research shows that enzalutamide can effectively control tumor growth, relieve symptoms caused by cancer, and improve patients' quality of life.

Enzalutamide is used not only to treat castration-resistant prostate cancer but has also shown efficacy in high-risk locally advanced prostate cancer and metastatic prostate cancer. For some men with high-risk prostate cancer detected early, enzalutamide can slow the progression of the disease when used in combination with other treatments. Enzalutamide is particularly effective in reducing the risk of cancer recurrence in patients who have undergone prostatectomy or radiation therapy. In addition, enzalutamide has also shown good clinical efficacy in the treatment of metastatic prostate cancer, especially in patients who have received other treatments that have failed.

Reference materials:https://www.xtandi.com/